Oral Fluoropyrimidines Among the New Drugs for Patients With Metastatic Breast Cancer

British Journal of Cancer - United Kingdom
doi 10.1054/bjoc.2001.1819
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Eribulin Suppresses New Metastases in Patients With Metastatic Breast Cancer

In Vivo
BiochemistryMedicineGeneticsPharmacologyMolecular Biology
2020English

Oral Paclitaxel in the Treatment of Metastatic Breast Cancer (MBC) Patients.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2019English

Recent Developments in Bisphosphonates for Patients With Metastatic Breast Cancer

BMJ
2005English

The Impacts of Inclusion in Clinical Trials on Outcomes Among Patients With Metastatic Breast Cancer (MBC)

PLoS ONE
Multidisciplinary
2016English

New Drugs for Prevention of Breast Cancer Metastases

1999English

Basic Study for the Clinical Application of Fluoropyrimidines to Cancer Chemotherapy. Part I. Metabolism of Fluoropyrimidines in Cancer Patients.

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
1985English

Disease-Free Survival in Patients With Non-Metastatic Breast Cancer

Revista da Associacao Medica Brasileira
Medicine
2016English

Drug Therapy of Breast Cancer Patients With Metastatic Brain Lesions.

Malignant tumours
2015English

Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients With Hormone Receptor-Negative Metastatic Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy